促卵泡激素市场 - 全球产业规模、份额、趋势、机会和预测，按类型、按应用（不孕症治疗、辅助生殖应用、其他）、按地区和竞争进行细分，2020-2030 年预测

2024 年全球促卵泡激素市场价值为 18.6 亿美元，预计到 2030 年将达到 22.1 亿美元，预测期内复合年增长率为 5.84%。几十年来，全球促卵泡激素 (FSH) 市场一直是医疗保健产业的重要参与者。 FSH 是一种在人类生殖中发挥重要作用的重要激素，是生育疗法和激素替代疗法的基本组成部分。随着世界人口老化、不孕率上升以及人们对荷尔蒙相关疾病的认识不断提高，FSH 市场经历了显着的成长和创新。促卵泡激素由脑下垂体前叶产生，是男性和女性生殖系统的关键调节因子。在女性中，FSH 会刺激卵泡的生长并引发排卵。在男性中，它会刺激睪丸产生精子。 FSH 水平失调会导致各种生殖健康问题，包括不孕症、月经不规则和荷尔蒙失衡。即时诊断（POC）检测设备透过实现快速现场诊断彻底改变了医疗保健。在 FSH 市场，POC 设备使医疗保健提供者能够立即获得 FSH 测试结果，从而减少患者的等待时间并促进更快地做出治疗决策。这对生育诊所和生殖健康中心尤其有益。

全球人口正在老化，越来越多的女性因为延后生育而寻求生育治疗。这种人口趋势导致对基于 FSH 的提高生育能力的疗法的需求激增。随着医疗保健资讯传播的进步，人们对生育问题和荷尔蒙相关疾病的认识不断提高，促使更多人寻求医疗协助，从而推动 FSH 市场的成长。生物技术和製药领域的创新促进了更有效的 FSH 产品和疗法的开发，从而提供了更好的效果并减少了副作用。许多国家的政府已采取措施支持辅助生殖技术和荷尔蒙替代疗法。其中包括补贴治疗、减少监管障碍和资助该领域的研究。

主要市场驱动因素

不孕症盛行率的上升推动了全球促卵泡激素市场的发展

主要市场挑战

生育治疗费用高昂

主要市场趋势

技术进步

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球促卵泡激素市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（重组 FSH、尿液 FSH）
  • 依应用分类（不孕症治疗、辅助生殖应用 (ART)、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美促卵泡激素市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲促卵泡激素市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区促卵泡激素市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲促卵泡激素市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲促卵泡激素市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Midas Pharma GmbH
• Creative BioMart inc.
• Genpharm Services
• Merck KgAa
• Livzon Pharmaceutical Group Inc
• Shanghai Techwell Biopharmaceutical Co., Ltd
• Medix Biochemica USA Inc.
• Biogenix Inc.Pvt.Ltd.

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Follicle Stimulating Hormone Market was valued at USD 1.86 Billion in 2024 and is expected to reach USD 2.21 Billion by 2030 with a CAGR of 5.84% during the forecast period. The global Follicle Stimulating Hormone (FSH) market has been a critical player in the healthcare industry for decades. FSH is a vital hormone that plays a significant role in human reproduction, making it a fundamental component of fertility treatments and hormone replacement therapy. As the world's population continues to age, infertility rates rise, and awareness about hormone-related disorders increases, the FSH market has witnessed significant growth and innovation. Follicle Stimulating Hormone, produced by the anterior pituitary gland, is a key regulator of the reproductive system in both men and women. In females, FSH stimulates the growth of ovarian follicles and triggers ovulation. In males, it stimulates the testes to produce sperm. Dysregulation of FSH levels can lead to various reproductive health issues, including infertility, irregular menstrual cycles, and hormone imbalances. Point-of-Care (POC) Testing devices have revolutionized healthcare by enabling rapid and on-site diagnostics. In the FSH market, POC devices have made it possible for healthcare providers to obtain immediate FSH test results, reducing patient wait times and facilitating faster treatment decisions. This is particularly beneficial for fertility clinics and reproductive health centers.

The global population is aging, with an increasing number of women seeking fertility treatments as they delay parenthood. This demographic trend has led to a surge in demand for FSH-based therapies to enhance fertility. Increasing awareness about fertility issues and hormone-related disorders, driven by advancements in healthcare information dissemination, has encouraged more people to seek medical assistance, thereby driving FSH market growth. Innovations in the field of biotechnology and pharmaceuticals have led to the development of more effective FSH products and therapies, offering improved results and fewer side effects. Governments in many countries have taken steps to support assisted reproductive technologies and hormone replacement therapies. This includes subsidizing treatments, reducing regulatory barriers, and funding research in the field.

Key Market Drivers

Increasing Prevalence of Infertility is Driving the Global Follicle Stimulating Hormone Market

Infertility has become a growing concern worldwide, affecting millions of couples who dream of starting a family. In recent years, the prevalence of infertility has been on the rise, contributing to the expansion of the global Follicle Stimulating Hormone (FSH) market. As per the World Health Organization's data updated in April 2023, approximately 1 in 6 adults globally are affected by infertility. FSH, a crucial hormone for reproductive health, has gained prominence as a key player in fertility treatments. Infertility is a medical condition defined by the inability to conceive after a year of regular, unprotected sexual intercourse. It can result from various factors, including hormonal imbalances, age-related declines in fertility, structural issues, and lifestyle factors. Changing societal trends, including delayed marriages and career-focused lifestyles, have led many couples to postpone starting a family until later in life. Unfortunately, female fertility declines with age, making conception more challenging. Environmental toxins, pollutants, and the exposure to endocrine-disrupting chemicals have been linked to fertility issues. These factors can disrupt hormonal balance, including FSH levels, crucial for healthy reproductive function. The modern lifestyle, characterized by high stress levels, sedentary habits, and poor dietary choices, can negatively impact fertility. Stress hormones can interfere with reproductive hormones, including FSH. According to the

Key Market Challenges

High Cost of Fertility Treatments

One of the major challenges facing the Global Follicle Stimulating Hormone (FSH) Market is the high cost of fertility treatments, which often limits accessibility for a significant portion of the population. While FSH is essential for assisted reproductive technologies (ART) like in vitro fertilization (IVF), the overall cost of these procedures can be prohibitively expensive, particularly in low- and middle-income countries. The cost of FSH injections, along with the additional expenses associated with IVF cycles, such as diagnostic tests, consultations, and hospital stays, creates financial barriers for many individuals seeking fertility treatments. Multiple rounds of IVF may be required for success, further escalating costs. Despite the growing availability of fertility insurance in some regions, many patients still struggle with the affordability of these therapies. This economic challenge hinders market growth, as the high cost limits the number of people who can access and afford treatment. To overcome this barrier, there is a need for more affordable treatment options, government subsidies, and broader insurance coverage to make fertility treatments more accessible globally.

Key Market Trends

Technological Advancements

The field of medicine and healthcare is continuously evolving, with technological advancements playing a pivotal role in shaping the future of diagnostics and treatments. One such area experiencing significant growth is the global Follicle Stimulating Hormone (FSH) market. FSH is a critical hormone responsible for regulating the reproductive system in both men and women. The market for FSH has been witnessing remarkable growth, largely driven by advancements in technology and a growing demand for fertility treatments and diagnostic tools. One of the key technological advancements in the FSH market is the development of highly sensitive assays for FSH measurement. Traditional FSH assays were relatively less precise and had limitations in detecting low levels of the hormone. However, modern immunoassays and automated platforms have greatly improved the accuracy and sensitivity of FSH testing. This has made it easier for healthcare professionals to diagnose and monitor reproductive disorders with precision. Advances in microfluidics and biosensor technologies have led to the development of user-friendly home fertility testing kits. These kits allow individuals to monitor their FSH levels at home, providing valuable insights into their reproductive health. Such technology empowers individuals to take control of their fertility and seek medical intervention when necessary.

Key Market Players

• Merck KgAa
• Creative BioMart inc.
• Midas Pharma GmbH
• Genpharm Services
• Livzon Pharmaceutical Group Inc
• Shanghai Techwell Biopharmaceutical Co., Ltd
• Medix Biochemica USA Inc.
• Biogenix Inc.Pvt.Ltd.

Report Scope:

In this report, the Global Follicle Stimulating Hormone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicle Stimulating Hormone Market, By Type:

• Recombinant FSH
• Urinary FSH

Follicle Stimulating Hormone Market, By Application:

• Infertility Treatment
• Assisted Reproductive Application (ART)
• Others

Follicle Stimulating Hormone Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Follicle Stimulating Hormone Market.

Available Customizations:

Global Follicle Stimulating Hormone market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicle Stimulating Hormone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Recombinant FSH, Urinary FSH)
  • 5.2.2. By Application (Infertility Treatment, Assisted Reproductive Application (ART), Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Follicle Stimulating Hormone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Follicle Stimulating Hormone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Follicle Stimulating Hormone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Follicle Stimulating Hormone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Follicle Stimulating Hormone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Follicle Stimulating Hormone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Follicle Stimulating Hormone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Follicle Stimulating Hormone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. France Follicle Stimulating Hormone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Follicle Stimulating Hormone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Follicle Stimulating Hormone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Follicle Stimulating Hormone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Follicle Stimulating Hormone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Follicle Stimulating Hormone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Follicle Stimulating Hormone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Follicle Stimulating Hormone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. South America Follicle Stimulating Hormone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Follicle Stimulating Hormone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Follicle Stimulating Hormone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Follicle Stimulating Hormone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Follicle Stimulating Hormone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Follicle Stimulating Hormone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Follicle Stimulating Hormone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Follicle Stimulating Hormone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Midas Pharma GmbH
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Creative BioMart inc.
• 14.3. Genpharm Services
• 14.4. Merck KgAa
• 14.5. Livzon Pharmaceutical Group Inc
• 14.6. Shanghai Techwell Biopharmaceutical Co., Ltd
• 14.7. Medix Biochemica USA Inc.
• 14.8. Biogenix Inc.Pvt.Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer